GSK awards 10,050 shares each to two plan participants

GSK disclosed share awards under its 2025 Share Value Plan to its company secretary and a person closely associated with a senior regional executive.

Rhea-AI Filing Summary

GSK plc (GSK) reports awards of Ordinary Shares under its 2025 Share Value Plan. On September 8, 2026, Victoria Whyte, SVP & Company Secretary, received an award of 10,050 Ordinary Shares at a reference price of £17.9650 per share.

On the same date, Neil Falkingham, a person closely associated with Lynn Baxter (President, Europe), also received an award of 10,050 Ordinary Shares at a reference price of £17.9650 per share under the same plan.

Key Figures

Shares awarded to Victoria Whyte: 10,050 Ordinary Shares Shares awarded to Neil Falkingham: 10,050 Ordinary Shares Reference price per share: £17.9650 per Ordinary Share +1 more

4 metrics

Shares awarded to Victoria Whyte 10,050 Ordinary Shares Award under the 2025 Share Value Plan on September 8, 2026

Shares awarded to Neil Falkingham 10,050 Ordinary Shares Award under the 2025 Share Value Plan on September 8, 2026

Reference price per share £17.9650 per Ordinary Share Used for both awards under the 2025 Share Value Plan

Transaction date September 8, 2026 Date of both share awards

Key Terms

PDMR, person closely associated, 2025 Share Value Plan, Ordinary Shares

4 terms

PDMR regulatory

"Details of PDMR/person closely associated with them"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

person closely associated regulatory

"Details of PDMR/person closely associated with them"

2025 Share Value Plan financial

"Award of Ordinary Shares under the Company’s 2025 Share Value Plan"

Ordinary Shares financial

"Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What executive share awards did GSK (GSK) disclose in this 6-K?

GSK disclosed awards of Ordinary Shares under its 2025 Share Value Plan to SVP & Company Secretary Victoria Whyte and to Neil Falkingham, a person closely associated with Lynn Baxter, President, Europe. Each received an award of 10,050 Ordinary Shares.

How many GSK (GSK) shares were awarded to Victoria Whyte?

Victoria Whyte received an award of 10,050 Ordinary Shares in GSK plc on September 8, 2026 under the company’s 2025 Share Value Plan, at a reference price of £17.9650 per share.

Who is Neil Falkingham in relation to GSK (GSK) and what award did he receive?

Neil Falkingham is identified as a person closely associated with Lynn Baxter, President, Europe at GSK. On September 8, 2026, he received an award of 10,050 Ordinary Shares at a reference price of £17.9650 per share under the 2025 Share Value Plan.

What is the reference price of the GSK (GSK) share awards reported?

Both reported awards of Ordinary Shares under GSK’s 2025 Share Value Plan used a reference price of £17.9650 per share for the 10,050-share awards granted on September 8, 2026.

Which share plan was used for the GSK (GSK) awards disclosed?

The awards were made under GSK’s 2025 Share Value Plan. Under this plan, both Victoria Whyte and Neil Falkingham received awards of 10,050 Ordinary Shares each on September 8, 2026 at a reference price of £17.9650 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 10:45 AM Accepted by SEC EDGAR 09/09/2026 - 10:45 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Award of Ordinary Shares under the Company’s 2025 Share Value Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£17.9650	10,050
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-09-08
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Award of Ordinary Shares under the Company’s 2025 Share Value Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£17.9650	10,050
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-09-08
f)	Place of the transaction	N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: September 09, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc